Articles On Dimerix (ASX:DXB)

Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Dimerix (ASX: DXB) has announced new data showing the efficacy of its pipeline program, DMX-700, in an industry-standard preclinical model of chronic obstructive pulmonary disease.

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

Dimerix continues to develop new therapies in areas with unmet medical needs for global markets, now showing potential as a treatment for chronic obstructive pulmonary disease (COPD). Aussie clinical stage biotech Dimerix (ASX:DXB)  today a...

Dimerix (DXB) releases its pipeline program DMX-700 study results which indicates a significant 80 per cent reduction in lung injury in mice The study showed “very encouraging and statistically significant” pre-clinical data that strongly...

Recruitment into a key study into Dimerix’s DMX-200 in all COVID-19 patients has now closed with results expected to start being analysed shortly. Aussie clinical stage biotech Dimerix (ASX:DXB)  today announced that REMAP-CAP has formally...

Dimerix (DXB) formally closes recruitment of moderate state COVID-19 patients for REMAP-CAP’s renin angiotensin system (RAS) domain clinical study This is to allow for the full results of this domain to be analysed and reported, which incl...

Dimerix (ASX:DXB) has entered into an agreement with The Australian Centre for Accelerating Diabetes Innovations to progress its DMX-200 into a new clinical trial in patients with diabetic kidney disease.

Dimerix will work with a key Australian diabetic organisation to start a trial on patients with diabetic kidney disease, in which there are currently no effective treatments. Aussie clinical stage biotech Dimerix (ASX:DXB) has entered into...

Dimerix (DXB) partners with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its DMX-200 drug in a new clinical trial in patients with diabetic kidney disease The company says this trial provides a potential mark...

Dimerix (ASX:DXB) has announced the recruitment of the first patient to its DMX-200 phase 3 trial in patients with FSGS kidney disease.

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

Dimerix (DXB) recruits the first patient to its ACTION3 phase 3 DMX-200 clinical trial in patients with FSGS kidney disease The trial is randomised, double-blind and placebo-controlled to evaluate the efficacy and safety of patients with F...

The ACTION3 Phase 3 clinical trial conducted by Dimerix will study the effects of its lead drug, DMX-200, on patients with FSGS kidney disease. Aussie clinical stage biotech Dimerix (ASX:DXB) has completed a significant milestone in its  AC...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

Dimerix (ASX:DXB) has received approval from the US FDA to proceed with the Phase 3 study of DMX-200 in patients with focal segmental glomerulosclerosis.

Dimerix (DXB) receives approval from the US FDA to proceed with a phase three study of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) An Investigational New Drug (IND) application for the study, dubbed ACTION3, is now a...

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

The company also added some important updates post quarter-end for its leading Phase 3 FSGS study. Clinical stage biotech Dimerix (ASX:DXB) confirmed another round of strong progress in its globally recognised development pathway, with the...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Dimerix (ASX:DXB) has announced it has received an R&D Tax Incentive rebate of $3.695 million for the 2020-21 year.

International Women’s Day is a day to celebrate the achievements of women worldwide, who are breaking down barriers and building paths for others to follow but it also a time to reflect on what else needs to be done to ensure more glass cei...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Dimerix’s study in COVID-19 patients in Europe is being adapted after the independent safety data monitoring board highlighted concerns with other treatment arms not connected to its lead compound DMX-200. Clinical stage biopharma Dimerix...

The ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down 5.6% over the last 52 weeks. The ASX Emerging Companies (XEC) index ended 0.6% better. The Four Horsemen of the Apocalypse are abroad on Mon...

Disclosure: The authors of this article and owners of Finfeed , S3 Consortium Pty Ltd, and associated entities, own 2,825,000 DXB shares at the time of writing. S3 Consortium Pty Ltd has been engaged by DXB to share our commentary on the pr...

Dimerix (DXB) pauses recruitment of COVID-19 patients with COVID-19 for its clinical study after safety issues were observed in patients with severe COVID-19 The Independent Data Safety Monitoring Board’s (DSMB) scheduled interim safety as...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The company remains well-funded to advance its clinical development pathway, as it looks to execute on a lucrative market opportunity. Clinical-stage biopharma company Dimerix (ASX:DXB) released its half-year results this morning, accompani...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Dimerix (ASX: DXB) has announced the appointment of Dr Ash Soman as chief medical officer and a member of its executive management team.

Disclosure: The authors of this article and owners of Finfeed, S3 Consortium Pty Ltd, and associated entities, own 2,825,000 DXB shares at the time of writing this article. S3 Consortium Pty Ltd has been engaged by DXB to share our commenta...

Two studies involving the use of DMX-200 are advancing rapidly, as part of global research efforts to develop improved treatment solutions for COVID-19 respiratory failure. For Dimerix (ASX:DXB), 2022 is shaping up as a busy year as it exec...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

Dimerix (ASX:DXB) says the first patients have been dosed in the India-based CLARITY 2.0 feasibility/Phase 3 study of DMX-200 as a potential new treatment for respiratory complications associated with COVID-19.

Highlights The ASX 200 fell 0.39% or 28.7 points to 7,409.1 in the first five minutes of trading. The 10-year Treasury yield in the US hit a two-year high on Monday. Nine out of the 11 sectors were trading in the red zone. The Aus...

Biopharmaceutical company Dimerix (DXB) doses its first patients with its inflammatory disease treatment, DMX-200, in India The company is currently studying its DMX-200 as a potential new treatment for respiratory complications associate...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Christmas has come early for Dimerix with Australian ethics approval granted for a Phase 3 clinical trial of its DMX-200 drug in COVID-19 patients with pneumonia respiratory complications. As the latest Omicron variant fuels COVID-19 cases...

Dimerix (DXB) has received Australian ethics approval for its phase three COVID-19 study, dubbed CLARITY 2.0 This approval is from the Research Ethics and Governance Office Ethics Committee and is for trialing DMX-200 in patients with COVI...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The further grant from the government will expedite the progress of Dimerix’ novel COVID-19 drug DMX-200 into possible commercialisation. Dimerix (ASX:DXB) has just received further funding from the Australian government  to support the com...